Press releasePRNewswire
Neurocrine Biosciences
NBIX · NASDAQ
$142.00+$5.02 (+3.66%)TodayMarket closed ·
Prev close $136.98
Latest news
- Press releasePRNewswire
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
- Press releasePRNewswire
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
- Press releasePRNewswire
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
- Press releasePRNewswire
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
- Press releasePRNewswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
- News
10 Health Care Stocks Whale Activity In Today’s Session
- NewsAvi Kapoor
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
- NewsVandana Singh
What's Going On With Neurocrine Biosciences Stock On Wednesday?
- Press releasePRNewswire
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
- Press releasePRNewswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
- News
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate
- Press releasePRNewswire
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
- Press releasePRNewswire
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
- Press releasePRNewswire
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
- Press releasePRNewswire
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
- Press releasePRNewswire
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
- Press releasePRNewswire
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
- Press releasePRNewswire
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
- Press releasePRNewswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
- Press releasePRNewswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
- NewsChandrima Sanyal
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys
- Press releasePRNewswire
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
- Press releasePRNewswire
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
- Press releasePRNewswire
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
- Press releasePRNewswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
- Press releasePRNewswire
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
- Press releasePRNewswire
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
- News
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate
- Press releasePRNewswire
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
- Press releasePRNewswire
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
- News
Earnings Scheduled For May 5, 2026
- NewsVandana Singh
Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market
- Press releasePRNewswire
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
- NewsVandana Singh
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
- News
Forecasting The Future: 10 Analyst Projections For Neurocrine Biosciences
- News
Neurocrine Biosciences Q4 Earnings Assessment
- NewsAvi Kapoor
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.